Craig E. Fraser, who currently serves as the Company’s President, Chief Executive Officer and Chairman of the Board of Directors, will assume the responsibilities of principal financial officer for purposes of the Securities Exchange Act of 1934, as amended, on an interim basis.
On February 15, 2024, Windtree Therapeutics, Inc. (the “Company”) and John A. Tattory mutually agreed to Mr. Tattory’s resignation from his positions as the Interim Chief Financial Officer and principal financial officer of the Company, effective February 15, 2024.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Craig E. Fraser was appointed as Principal Financial Officer at WINDTREE THERAPEUTICS INC /DE/.
Action
assumed
Role
Principal Financial Officer
Exact text from the filing
Craig E. Fraser, who currently serves as the Company’s President, Chief Executive Officer and Chairman of the Board of Directors, will assume the responsibilities of principal financial officer for purposes of the Securities Exchange Act of 1934, as amended, on an interim basis.
John A. Tattory resigned as Interim Chief Financial Officer at WINDTREE THERAPEUTICS INC /DE/.
Action
resigned
Role
Interim Chief Financial Officer
Exact text from the filing
On February 15, 2024, Windtree Therapeutics, Inc. (the “Company”) and John A. Tattory mutually agreed to Mr. Tattory’s resignation from his positions as the Interim Chief Financial Officer and principal financial officer of the Company, effective February 15, 2024.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.